Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer

Overall survival in a phase III study for metastatic pancreatic cancer has significantly improved with gemcitabine (GEM) plus nab-paclitaxel. However, to date, there is limited data on the efficacy and safety of its use for patients with locally advanced (LA) or borderline resectable pancreatic canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsujimoto, Akiko, Sudo, Kentaro, Nakamura, Kazuyoshi, Kita, Emiri, Hara, Ryusuke, Takayama, Wataru, Ishii, Hiroshi, Yamaguchi, Taketo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838159/
https://www.ncbi.nlm.nih.gov/pubmed/31700023
http://dx.doi.org/10.1038/s41598-019-52486-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838159/
https://www.ncbi.nlm.nih.gov/pubmed/31700023
http://dx.doi.org/10.1038/s41598-019-52486-x

Ejemplares similares